ATE397457T1 - Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen - Google Patents

Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen

Info

Publication number
ATE397457T1
ATE397457T1 AT99965991T AT99965991T ATE397457T1 AT E397457 T1 ATE397457 T1 AT E397457T1 AT 99965991 T AT99965991 T AT 99965991T AT 99965991 T AT99965991 T AT 99965991T AT E397457 T1 ATE397457 T1 AT E397457T1
Authority
AT
Austria
Prior art keywords
ctla
stimulation
antigens
against self
cells against
Prior art date
Application number
AT99965991T
Other languages
English (en)
Inventor
James Allison
Arthur Hurwitz
Andrea Vanelsas
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE397457T1 publication Critical patent/ATE397457T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99965991T 1998-12-03 1999-12-03 Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen ATE397457T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11076198P 1998-12-03 1998-12-03

Publications (1)

Publication Number Publication Date
ATE397457T1 true ATE397457T1 (de) 2008-06-15

Family

ID=22334796

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965991T ATE397457T1 (de) 1998-12-03 1999-12-03 Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen

Country Status (11)

Country Link
EP (1) EP1137436B1 (de)
JP (1) JP5341287B2 (de)
AT (1) ATE397457T1 (de)
AU (1) AU774962B2 (de)
CA (1) CA2352783C (de)
CY (1) CY1108318T1 (de)
DE (1) DE69938871D1 (de)
DK (1) DK1137436T3 (de)
ES (1) ES2308857T3 (de)
PT (1) PT1137436E (de)
WO (1) WO2000032231A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
JP2004501631A (ja) 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1240436C (zh) * 2002-08-28 2006-02-08 上海益众生物技术有限公司 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用
WO2004081021A2 (en) * 2003-03-12 2004-09-23 Duke University Oligonucleotide mimetics
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7494779B2 (en) 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EP3214095B1 (de) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Zusammensetzungen und verfahren zur modulation von immunsystemreaktionen
CN101355965A (zh) 2005-06-08 2009-01-28 达纳－法伯癌症研究院 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1954311A4 (de) 2005-12-07 2009-12-23 Medarex Inc Ctla-4-antikörper-dosierungseskalationstherapien
CA2744449C (en) 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
EP3375791A1 (de) 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Kombinationsimmuntherapie zur behandlung von krebs
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
AU2013255511B2 (en) * 2012-05-04 2016-01-28 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JP6723153B2 (ja) 2013-12-05 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 生体内の望ましくない軟部組織を切除するシステム
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (de) 2014-01-31 2019-03-27 Novartis AG Antikörpermoleküle mit tim-3 und verwendungen davon
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
DK3240801T3 (da) 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對ｉｃｏｓ之抗體
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3365372A1 (de) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gensignaturen zur bestimmung der icos-expression
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
EP3402517B1 (de) 2016-01-15 2025-08-20 RFEMB Holdings, LLC Immunologische behandlung von krebs unter verwendung einer tumorablationstechnik zusammen mit einer kombination eines ctla-4-inhibitors, eines pd-1-inhibitors und gm-csf
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CN110366565A (zh) 2017-02-28 2019-10-22 百时美施贵宝公司 具有增强的adcc的抗ctla-4抗体增强对疫苗的免疫应答的用途
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
KR102890791B1 (ko) 2018-04-09 2025-11-24 체크메이트 파마슈티칼스, 인크. 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
US20210236694A1 (en) * 2018-05-03 2021-08-05 The Johns Hopkins University Induction of anti-tumoral immune microenvironments
EP3861016A2 (de) 2018-10-03 2021-08-11 Xencor, Inc. Il-12-heterodimere fc-fusionsproteine
AU2019359475A1 (en) 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
CN115916233A (zh) 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP7405361B2 (ja) 2019-10-21 2023-12-26 東亞合成株式会社 抗腫瘍ペプチドおよびその利用
JP7498889B2 (ja) 2020-01-30 2024-06-13 東亞合成株式会社 Ｃｔｌａ４とｂ７タンパク質との結合を抑制するペプチドおよびその利用
JP2026505276A (ja) 2023-01-31 2026-02-13 ユニバーシティ オブ ロチェスター Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ感染症を治療するための免疫チェックポイント遮断療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) * 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same

Also Published As

Publication number Publication date
JP2002531416A (ja) 2002-09-24
DE69938871D1 (de) 2008-07-17
EP1137436A1 (de) 2001-10-04
CA2352783C (en) 2012-04-10
AU774962B2 (en) 2004-07-15
CA2352783A1 (en) 2000-06-08
CY1108318T1 (el) 2014-02-12
DK1137436T3 (da) 2008-10-13
AU2164900A (en) 2000-06-19
EP1137436B1 (de) 2008-06-04
ES2308857T3 (es) 2008-12-01
WO2000032231A1 (en) 2000-06-08
JP5341287B2 (ja) 2013-11-13
PT1137436E (pt) 2008-09-15

Similar Documents

Publication Publication Date Title
ATE397457T1 (de) Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
SE9700182D0 (sv) Implantable heart stimulator
ATE552849T1 (de) Behandlungsverfahren unter verwendung von ctla-4 antikörpern
DE69814394D1 (de) Verwendung von levobupivacain
BR9908082A (pt) Proteìna de fusão do complexo de histocompatibilidade principal classe ii, conjugado dos domìnios de ligação do complexo de histocompatibilidade principal multimérico, processos para detectar células t tendo uma especificidade do complexo definido de mhc / peptìdeo, para conferir a um indivìduo imunidade adotiva a um complexo definido de mhc / peptìdeo, para estimular ou ativar as células t reativas a um complexo definido de mhc / peptìdeo, para seletivamente matar células t reativas a um complexo definido de mhc / peptìdeo, para tolerizar um indivìduo humano a um complexo definido de mhc / peptìdeo, e, ácido nucleico isolado
ATE324119T1 (de) Verwendung von saccharid-konjugaten
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
EA199900045A1 (ru) Производные спиропиперидина и их использование в качестве терапевтических агентов
DK0749323T3 (da) Fremgangsmåder til modulering af T-celle-anergi
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
CY1106046T1 (el) Μεθοδος για την θεραπευτικη αγωγη ινωσεως με χρησιμοποιηση ενος ανταγωνιστου της αλφα-4-υπομοναδος της ιντεγκρινης
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
GB0102145D0 (en) Substances
PT818973E (pt) Dispositivo biodegradavel
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
FR2774916B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
EP0971725A4 (de) Verfahren zur behandlung von narbengewebe
DE69815822D1 (de) Verwendung der angiotensin ii-antagonisten losartan und exp-3174 zur behandlung von symptomatisches herzversagen
NO20060637L (no) Autologe selv-toleranse induserende celler av monocytisk opprinnelse og deres anvendelse i farmasoytiske preparater

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1137436

Country of ref document: EP